FEBS Letters · 2012 · 82 citations · 12 references
MedicineOncologyPharmacologyCell SignalingSignal TransductionTumor MicroenvironmentAngiogenesisAngiogenesis In CancerG Protein-coupled Receptor SignalingNeurotransmitter ReceptorsPlatelet AggregationSerotonergic SignalingNeurotransmitter PharmacologyPi3k-akt Signaling PathwayPi3k-akt-mtor SignalingResistance To Antiangiogenic TherapySerotonin Receptor SignalingSerotonin ReceptorsTumor Angiogenesis SignalingVascular Endothelial Growth Factor
Serotonin, a known neurotransmitter, also functions as an angiokine to promote angiogenesis. The majority of serotonin in the human body is stored in platelets, and platelet aggregation leads to significant release of serotonin in thrombotic tumor environment. We have investigated serotonin signaling in human endothelial cells. Through G-protein-coupled receptors, serotonin at physiologically relevant concentrations activated Src/PI3K/AKT/mTOR/p70S6K phosphorylation signaling, and this activation was similar to that seen with VEGF. This finding provides insight into the overlapping angiogenic signaling pathways stimulated by serotonin in tumor environment, and suggests one of the mechanisms underlying resistance to current VEGF-targeting antiangiogenic therapy against cancer.
12
Emilie Zifa, G. Fillion · Trends in Pharmacological Sciences · 2001 · 682 citations
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Yaning Wang, David Fei, Martin Vanderlaan et al. · Angiogenesis · 2004 · 437 citations
Medicine, Cancer Biology, Oncology +14